It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis.
His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from an Open Label Extension Trial’ was given at the EADV 30th Congress, 29 Sep – 2 Oct.
- Could you give us a brief overview of dupilumab and upadacitinib, their mechanisms of action and their means of administration? (0:15)
- What is the rationale for switching from dupilumab to upadacitinib in the treatment of moderate-to-severe atopic dermatitis? (1:26)
- Could you tell us a little about the methodology of your clinical trial? (2:15)
- What were the findings of the open-label extension study and what are their clinical implications? (2:55)
- How likely is it in the future that upadacitinib will replace dupilumab as first-line treatment of moderate-to-severe atopic dermatitis? (4:23)
Disclosures: Dr Andy Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Matthew Goodwin.
Filmed in coverage of the EADV’s 30th Congress, 29 Sep – 2 Oct 2021.
Share this Video
Related Videos In Atopic Dermatitis
Gil Yosipovitch, EADV 2022: Lebrikizumab Monotherapy for Moderate to Severe Atopic Dermatitis
ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967) are phase 3, randomised, double-blind, placebo-controlled trials, investigating lebrikizumab monotherapy in moderate to severe atopic dermatitis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) around the ADvocate 1 and ADvocate 2 phase 3 studies and the findings from his […]
Laura Carucci, EAACI 2022: Probiotic L.rhamnosus GG in Paediatric Atopic Dermatitis – Findings from the ProPAD Study
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the aims, outcome measures and findings from the ProPAD study, investigating L.rhamnosus GG in paediatric atopic dermatitis. The abstract […]
Laura Carucci, EAACI 2022: Health Burden of Paediatric Atopic Dermatitis and Impact of Probiotic Treatment
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the health burden of paediatric atopic dermatitis, the unmet needs in treatment and the potential of probiotic treatment. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!